Two Sigma Investments
OCUL icon

Two Sigma Investments’s Ocular Therapeutix OCUL Stock Holding History

Two Sigma Investments’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
1,830,159
+1,449,446
+381% +$13.8M 0.01% 1118
2025
Q4 		$4.62M Buy
380,713
+146,500
+63% +$1.78M 0.01% 1783
2025
Q3 		$2.74M Buy
234,213
+123,381
+111% +$1.48M ﹤0.01% 1920
2025
Q2 		$1.03M Sell
110,832
-350,398
-76% -$2.74M ﹤0.01% 2228
2025
Q1 		$3.38M Buy
461,230
+208,291
+82% +$1.6M 0.01% 1366
2024
Q4 		$2.16M Buy
252,939
+45,518
+22% +$444K ﹤0.01% 1660
2024
Q3 		$1.8M Sell
207,421
-328,698
-61% -$2.71M ﹤0.01% 1740
2024
Q2 		$3.67M Buy
536,119
+516,706
+2,662% +$3.19M 0.01% 1156
2024
Q1 		$177K Sell
19,413
-91,587
-83% -$650K ﹤0.01% 2743
2023
Q4 		$495K Sell
111,000
-5,100
-4% -$15.1K ﹤0.01% 2465
2023
Q3 		$365K Sell
116,100
-20,200
-15% -$82.7K ﹤0.01% 2414
2023
Q2 		$703K Sell
136,300
-187,124
-58% -$1.11M ﹤0.01% 2163
2023
Q1 		$1.7M Buy
323,424
+134,339
+71% +$638K ﹤0.01% 1492
2022
Q4 		$531K Sell
189,085
-8,675
-4% -$28.7K ﹤0.01% 1994
2022
Q3 		$821K Buy
+197,760
New +$996K ﹤0.01% 1549
2022
Q2 		– Sell
-483,284
Closed -$2.39M – 2815
2022
Q1 		$2.39M Buy
483,284
+13,418
+3% +$74.4K 0.01% 1269
2021
Q4 		$3.27M Sell
469,866
-425,534
-48% -$3.3M 0.01% 1509
2021
Q3 		$8.95M Sell
895,400
-140,645
-14% -$1.58M 0.02% 826
2021
Q2 		$14.7M Sell
1,036,045
-132,413
-11% -$2.01M 0.03% 618
2021
Q1 		$19.2M Buy
1,168,458
+248,163
+27% +$4.78M 0.05% 453
2020
Q4 		$19.1M Buy
920,295
+589,995
+179% +$8.76M 0.05% 391
2020
Q3 		$2.51M Buy
330,300
+141,385
+75% +$1.17M 0.01% 1167
2020
Q2 		$1.57M Buy
188,915
+164,554
+675% +$1.09M 0.01% 1231
2020
Q1 		$121K Buy
+24,361
New +$120K ﹤0.01% 2803
2019
Q2 		– Sell
-30,737
Closed -$122K – 3568
2019
Q1 		$122K Sell
30,737
-39,444
-56% -$159K ﹤0.01% 2877
2018
Q4 		$279K Buy
70,181
+51,186
+269% +$282K ﹤0.01% 2502
2018
Q3 		$131K Buy
+18,995
New +$119K ﹤0.01% 3057

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Investments's OCUL Position: Q1 2026 in Review

Two Sigma Investments increased its Ocular Therapeutix (OCUL) stake by 381% in Q1 2026, buying an estimated $13.8M and bringing the position to 1,830,159 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1118.

Two Sigma Investments first reported a position in OCUL in Q3 2018 and has held it in 27 quarters since. The position peaked at $19.2M in Q1 2021. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Two Sigma Investments held 1,830,159 shares of Ocular Therapeutix worth $15.5M as of Q1 2026.
  • Two Sigma Investments bought 1,449,446 Ocular Therapeutix shares in Q1 2026, an estimated $13.8M.
  • Ocular Therapeutix made up 0.01% of Two Sigma Investments's portfolio in Q1 2026, its #1118 holding.
  • Two Sigma Investments first reported a position in Ocular Therapeutix in Q3 2018 and has held it in 27 quarters since.
  • Two Sigma Investments's Ocular Therapeutix position peaked at $19.2M in Q1 2021.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.